Clinical trials: Stem Cell Mobilization
Defect of Articular Cartilage, Cartilage Injury
Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair
This is a proof-of-concept study to determine the safety and efficacy of a novel device to increase the reparative capacity of the knee.
- Conditions
- Defect of Articular Cartilage, Cartilage Injury, Osteoarthritis, Knee
- Trial name
- AURA (NCT02696876)
- Testing
- Arthroscopic synovial brushing, Microfracture
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University of Leeds
Ischemic Heart Disease
The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris
The aim of this study was to evaluate the mobilization of non-haematopoietic mesenchymal and haematopoietic stem cells from the bone marrow with granulocyte colony stimulating factor (G-CSF) treatment alone and in combination…
- Trial name
- NCT00135850
- Testing
- VEGF-A165 plasmid
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Background: Stem cell transplants from related donors (allogenic stem cell transplants) can be used to treat individuals with certain kinds of severe blood diseases or cancers, such as severe anemia.
- Trial name
- NCT01174108
- Testing
- Miltenyi CD34 Reagent System, Donor derived G-CSF mobilized PBC
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma
Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002510
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Temple University
Knee Arthroscopy Surgery, Knee Acute and Chronic Pain
Arthroscopic Infrapatellar Fat Pad Release and Mesenchymal Stem Cell Mobilization
This prospective, single-center, paired-sample clinical laboratory study evaluated whether controlled mechanical release of the infrapatellar fat pad during knee arthroscopy increases the number of intra-articular cells with a…
- Conditions
- Knee Arthroscopy Surgery, Knee Acute and Chronic Pain, Meniscal Tears
- Trial name
- IP-MSC-RELEASE (NCT07736716)
- Testing
- Controlled Mechanical Release of the Infrapatellar Fat Pad
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people
- Sponsor
- Ankara City Hospital Bilkent
Multiple Myeloma, Lymphoma
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5 after chemotherapy for autologous…
- Trial name
- NCT05294055
- Testing
- Etoposide, Cyclophosphamide, Mecapegfilgrastim, day 2
- Where
- 7 sites in China
- Volunteers
- 120 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Healthy Hematopoietic Stem Cell Donor, Healthy Allogeneic Hematopoietic Stem Cell Donor
Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors
National and international guidelines/consensus recommend G-CSF (granulocyte colony-stimulating factor) at 10 μg/kg/day as a single daily dose or divided into two daily doses for mobilization in healthy donors for allogeneic…
- Trial name
- NCT07692841
- Testing
- Single-dose Granulocyte colony-stimulating factor (G-CSF), Divided-dose Granulocyte colony-stimulating factor (G-CSF)
- Where
- 8 sites in China
- Volunteers
- 560 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Multiple Myeloma
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
The purpose of this study is to evaluate the effectiveness of Bortezomib when added to standard chemotherapy medicine(s) for treatment of Multiple Myeloma.
- Trial name
- NCT00948922
- Testing
- Bortezomib, Melphalan, Autologous Stem Cell Transplant
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
- Trial name
- GENESIS (NCT03246529)
- Testing
- BL-8040 1.25 mg/kg + G-CSF
- Where
- 18 sites in United States, Germany and 3 more
- Volunteers
- 180 people
- Sponsor
- BioLineRx, Ltd.